Strongbridge Biopharma plc Profit Margin

Strongbridge Biopharma plc (SBBP) currently reports a profit margin of -115.66% as of June 2021. That compares with -205.02% in the prior-year period — up 43.6% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Strongbridge Biopharma plc's profit margin history and peer comparisons.

Strongbridge Biopharma plc's profit margin increased from -205.02% to -115.66% — a 43.6% year-over-year increase (period ending June 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Strongbridge Biopharma plc's profit margin of -115.66% is lower than the Healthcare sector average of 19.13%. That is roughly 704.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Strongbridge Biopharma plc's current -115.66% should be judged against Healthcare norms (sector average: 19.13%) and against SBBP's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -115.66%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Strongbridge Biopharma plc, and consider following SBBP for alerts when major investors trade the stock.